Knowledge | Study Finds Pregnancy Safe for BRCA Mutation Carriers Without Increased Breast Cancer Recurrence Risk
A study published in the Journal of the American Medical Association offers encouraging news for young breast cancer survivors. It found that women with BRCA mutations can become pregnant after breast cancer treatment without increasing their risk of recurrence. The study examined nearly 5,000 women and found that 22% became pregnant, most through natural conception. Most showed no signs of breast cancer recurrence after pregnancy.
Study Background
BRCA mutations, especially BRCA1 and BRCA2 mutations, are known to be closely associated with a high incidence of breast cancer. These mutations not only increase cancer risk but may also affect female fertility. Providing effective fertility counseling, particularly about how pregnancy affects breast cancer recurrence risk, has therefore remained an important medical concern. Researchers found that many women with BRCA mutations worry about passing the mutation to their children while also facing diminished ovarian reserve and a risk of early-onset ovarian cancer, leaving a very narrow window for pregnancy between breast cancer treatment and risk-reducing surgery.
Study Results
The study followed 4,732 patients under age 40 with early-stage breast cancer, 659 of whom became pregnant after treatment. Breast cancer recurrence rates were nearly identical among women who became pregnant and those who did not, indicating that pregnancy itself did not increase recurrence risk. The analysis was also the largest study to date on the safety of pregnancy among BRCA mutation carriers.
During the study, about one in five women became pregnant within 10 years of their breast cancer diagnosis. Although the pregnancy rate does not necessarily reflect the likelihood of pregnancy because it is unclear how many women were actively trying to conceive, women who became pregnant were generally younger at cancer diagnosis, with a median age at delivery of about 35.
The results also showed that pregnant women did not experience more pregnancy complications or adverse outcomes than women who did not become pregnant. Of the 659 women who became pregnant, 517 gave birth, and about 10% of the deliveries were twins.
Pregnancy and Breast Cancer Recurrence
Notably, 90% of the treated breast cancer patients received chemotherapy. Given the association between chemotherapy and infertility, the results showed that women who became pregnant had both higher breast cancer-specific survival and better overall survival. The research team noted that women who become pregnant generally have a better prognosis, while those whose cancer recurs soon after diagnosis may be unable to become pregnant.
Lead author Dr. Matteo Lambertini, associate professor of oncology at the University of Genoa in Italy, said, “I do not believe pregnancy itself has a protective effect, but it is clear that pregnancy does not increase the risk of breast cancer recurrence.” He added, “Many oncologists still advise patients to avoid pregnancy because they fear it may increase the risk of recurrence, but our findings clearly show that pregnancy does not increase this risk.”
BRCA Mutations and Fertility Counseling
BRCA mutations are associated not only with a high incidence of breast cancer but also with an increased risk of ovarian cancer, often at a younger age. Studies show that women with BRCA mutations have a higher lifetime risk of breast cancer than the general population, with the risk particularly significant among women with BRCA2 mutations. To reduce ovarian cancer risk, many women choose preventive removal of the ovaries and fallopian tubes.
About half of the women in the study underwent this risk-reducing surgery, including 43% of those who became pregnant. The study also found differences in breast cancer recurrence risk between BRCA1 and BRCA2 mutation carriers. BRCA2 carriers had a higher recurrence rate, and their cancers were more likely to be hormone-sensitive, including sensitivity to estrogen. Even so, when researchers included all patients with hormone-sensitive breast cancer in the analysis, they found no overall increase in recurrence risk, indicating that fertility counseling should be tailored to each woman’s specific cancer type.
Summary and Recommendations
Although BRCA2 mutation carriers may need greater caution regarding pregnancy in some circumstances, Dr. Lambertini emphasized, “This study shows that pregnancy is safe for women with BRCA mutations. However, if BRCA2 mutation carriers have hormone-sensitive breast cancer, they are advised to complete five years of hormone therapy, such as tamoxifen, before becoming pregnant to reduce recurrence risk.”
Knowledge | Study Finds Pregnancy Safe for BRCA Mutation Carriers Without Increased Breast Cancer Recurrence Risk
Knowledge | Study Finds Pregnancy Safe for BRCA Mutation Carriers Without Increased Breast Cancer Recurrence Risk
A study published in the Journal of the American Medical Association offers encouraging news for young breast cancer survivors. It found that women with BRCA mutations can become pregnant after breast cancer treatment without increasing their risk of recurrence. The study examined nearly 5,000 women and found that 22% became pregnant, most through natural conception. Most showed no signs of breast cancer recurrence after pregnancy.
Study Background
BRCA mutations, especially BRCA1 and BRCA2 mutations, are known to be closely associated with a high incidence of breast cancer. These mutations not only increase cancer risk but may also affect female fertility. Providing effective fertility counseling, particularly about how pregnancy affects breast cancer recurrence risk, has therefore remained an important medical concern. Researchers found that many women with BRCA mutations worry about passing the mutation to their children while also facing diminished ovarian reserve and a risk of early-onset ovarian cancer, leaving a very narrow window for pregnancy between breast cancer treatment and risk-reducing surgery.
Study Results
The study followed 4,732 patients under age 40 with early-stage breast cancer, 659 of whom became pregnant after treatment. Breast cancer recurrence rates were nearly identical among women who became pregnant and those who did not, indicating that pregnancy itself did not increase recurrence risk. The analysis was also the largest study to date on the safety of pregnancy among BRCA mutation carriers.
During the study, about one in five women became pregnant within 10 years of their breast cancer diagnosis. Although the pregnancy rate does not necessarily reflect the likelihood of pregnancy because it is unclear how many women were actively trying to conceive, women who became pregnant were generally younger at cancer diagnosis, with a median age at delivery of about 35.
The results also showed that pregnant women did not experience more pregnancy complications or adverse outcomes than women who did not become pregnant. Of the 659 women who became pregnant, 517 gave birth, and about 10% of the deliveries were twins.
Pregnancy and Breast Cancer Recurrence
Notably, 90% of the treated breast cancer patients received chemotherapy. Given the association between chemotherapy and infertility, the results showed that women who became pregnant had both higher breast cancer-specific survival and better overall survival. The research team noted that women who become pregnant generally have a better prognosis, while those whose cancer recurs soon after diagnosis may be unable to become pregnant.
Lead author Dr. Matteo Lambertini, associate professor of oncology at the University of Genoa in Italy, said, “I do not believe pregnancy itself has a protective effect, but it is clear that pregnancy does not increase the risk of breast cancer recurrence.” He added, “Many oncologists still advise patients to avoid pregnancy because they fear it may increase the risk of recurrence, but our findings clearly show that pregnancy does not increase this risk.”
BRCA Mutations and Fertility Counseling
BRCA mutations are associated not only with a high incidence of breast cancer but also with an increased risk of ovarian cancer, often at a younger age. Studies show that women with BRCA mutations have a higher lifetime risk of breast cancer than the general population, with the risk particularly significant among women with BRCA2 mutations. To reduce ovarian cancer risk, many women choose preventive removal of the ovaries and fallopian tubes.
About half of the women in the study underwent this risk-reducing surgery, including 43% of those who became pregnant. The study also found differences in breast cancer recurrence risk between BRCA1 and BRCA2 mutation carriers. BRCA2 carriers had a higher recurrence rate, and their cancers were more likely to be hormone-sensitive, including sensitivity to estrogen. Even so, when researchers included all patients with hormone-sensitive breast cancer in the analysis, they found no overall increase in recurrence risk, indicating that fertility counseling should be tailored to each woman’s specific cancer type.
Summary and Recommendations
Although BRCA2 mutation carriers may need greater caution regarding pregnancy in some circumstances, Dr. Lambertini emphasized, “This study shows that pregnancy is safe for women with BRCA mutations. However, if BRCA2 mutation carriers have hormone-sensitive breast cancer, they are advised to complete five years of hormone therapy, such as tamoxifen, before becoming pregnant to reduce recurrence risk.”
Story source:
Collected online